N1BI34 Aktienübersicht Neurocrine Biosciences, Inc. erforscht, entwickelt und vermarktet Arzneimittel für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen in den Vereinigten Staaten und international. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Community vs My Fair Value Select a narrative for quick price alerts from the community, or create your own.
Neurocrine Biosciences, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Neurocrine Biosciences Historische Aktienkurse Aktueller Aktienkurs US$33.84 52-Wochen-Hoch US$44.95 52-Wochen-Tief US$25.64 Beta 0.26 1 Monat Veränderung 16.97% 3 Monate Veränderung 2.11% 1 Jahr Veränderung -6.73% 3 Jahre Veränderung 62.93% 5 Jahre Veränderung n/a Veränderung seit IPO 18.74%
Aktuelle Nachrichten und Updates Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 Cahtalyst™? Pediatric Study At Pediatric Endocrine Society 2025 Annual Meeting
Neurocrine Biosciences, Inc. Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia May 15
Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™? Pediatric Study May 08
Neurocrine Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2025 and Provides Sales Guidance for the Second Quarter of 2025 and Second Half of 2025 May 06
Neurocrine Biosciences, Inc. Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia Apr 30
Neurocrine Biosciences, Inc. Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGreZZA®? (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry Apr 25 Weitere Updates anzeigen Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 Cahtalyst™? Pediatric Study At Pediatric Endocrine Society 2025 Annual Meeting
Neurocrine Biosciences, Inc. Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia May 15
Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™? Pediatric Study May 08
Neurocrine Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2025 and Provides Sales Guidance for the Second Quarter of 2025 and Second Half of 2025 May 06
Neurocrine Biosciences, Inc. Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia Apr 30
Neurocrine Biosciences, Inc. Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGreZZA®? (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry Apr 25
Neurocrine Biosciences, Inc. to Report Q1, 2025 Results on May 05, 2025 Apr 15
Neurocrine Biosciences, Inc., Annual General Meeting, May 21, 2025 Apr 12
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer, Effective June 2, 2025 Apr 04
Neurocrine Biosciences, Inc. Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients with Tardive Dyskinesia Apr 01
Neurocrine Biosciences, Inc. Presents New Kinect® HD Data Showing Significant Reduction in Chorea Across Body Regions with Ingrezza® (Valbenazine) Capsules Mar 18
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, A Second-Generation Vmat2 Inhibitor, in Healthy Adults Mar 06
Neurocrine Biosciences Reports Patient-Reported Outcome Data from Kinect-Pro Study for INGREZZA (Valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures Feb 28
Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $500 million worth of its shares. Feb 21
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025 Feb 07
Neurocrine Biosciences, Inc. to Report Q4, 2024 Results on Feb 06, 2025 Jan 31
Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device Jan 24
Neurocrine Biosciences, Inc. Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia Jan 09
Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 20
Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 14
Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules Nov 08 Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules
Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares. Oct 30
Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia Sep 13
Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024 Aug 01
Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing Jul 18
Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH Jul 01 Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences Announces CEO Changes May 30
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis May 23
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 May 15
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 May 11
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults May 09
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 May 08
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024 May 03
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules May 02
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community Apr 25
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Apr 23 Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Apr 03
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Mar 28
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024 Feb 07
Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024 Jan 18 Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation Nov 15
Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial Nov 11
Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023 Nov 03
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023 Nov 01
Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation Sep 15
Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) Sep 14
Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults Sep 12
Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules Aug 30
Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease Aug 29
Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease Aug 19
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023 Aug 03
Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer Jul 14 Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023
Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate Jun 03
Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology May 20
Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 May 13
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023 May 04
Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023 Jan 18
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease Dec 24
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep Dec 08
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 Nov 04
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022 Nov 02
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia Oct 28
Neurocrine Biosciences, Inc. Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 Oct 25
Neurocrine Biosciences, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's Executive Management Team as Chief Regulatory Officer Effective October 1, 2022 Sep 30
Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 Sep 21 Neurocrine Biosciences, Inc. Announces to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians At 2022 MDS International Congress
Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of Fiscal 2022 Aug 06
Neurocrine Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 15
Neurocrine Biosciences, Inc. Presents Data on Sleep Disturbances and Off Time in Patients with Parkinson's Disease and Motor Fluctuations At Sleep 2022 Jun 07
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2022 May 05
Neurocrine Biosciences, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 14
Neurocrine Biosciences, Inc., Annual General Meeting, May 18, 2022 Apr 09
Neurocrine Biosciences Presents Phase 3 Data for Kinect-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease At AAN 2022 Apr 03
Neurocrine Biosciences Announces Positive Phase 3 Data Dec 08
Neurocrine Biosciences, Inc. to Present New INGREZZA (Valbenazine) and ONGENTYS (Opicapone) Data at the MDS Virtual Congress 2021 Sep 11
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease Aug 08 Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) dropped from Russell 1000 Growth-Defensive Index
Neurocrine Biosciences, Inc. to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021 Mar 21
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) Mar 04 Aktionärsrenditen N1BI34 BR Biotechs BR Markt 7D -1.7% 2.6% 1.8% 1Y -6.7% -9.3% 2.4%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: N1BI34 übertraf die Branche BR Biotechs , die im vergangenen Jahr eine Rendite von -9.3 erzielte.
Rendite vs. Markt: N1BI34 hinter dem Markt BR zurück, der im vergangenen Jahr eine Rendite von 2.4 erzielte.
Preisvolatilität Is N1BI34's price volatile compared to industry and market? N1BI34 volatility N1BI34 Average Weekly Movement n/a Biotechs Industry Average Movement 10.1% Market Average Movement 5.2% 10% most volatile stocks in BR Market 9.7% 10% least volatile stocks in BR Market 2.8%
Stabiler Aktienkurs: Es sind keine Daten verfügbar.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von N1BI34 im vergangenen Jahr zu bestimmen.
Über das Unternehmen Neurocrine Biosciences, Inc. erforscht, entwickelt und vermarktet Arzneimittel für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen in den Vereinigten Staaten und international. Zu den Produkten des Unternehmens gehören INGREZZA zur Behandlung von Spätdyskinesien und Chorea im Zusammenhang mit der Huntington-Krankheit, ALKINDI zur Behandlung von Nebenniereninsuffizienz, Efmody-Kapseln zur Behandlung der klassischen kongenitalen Nebennierenhyperplasie, Orilissa-Tabletten zur Behandlung von Endometriose, Oriahnn-Kapseln zur Behandlung von Uterusmyomen und CRENESSITY zur Behandlung der kongenitalen Nebennierenhyperplasie. Zu den Produktkandidaten in der klinischen Entwicklung gehören Valbenazin zur Behandlung von dyskinetischer Zerebralparese und Schizophrenie; NBI-1076986 zur Behandlung von Bewegungsstörungen; Osavampator zur Behandlung von unzureichendem Ansprechen auf eine Behandlung bei schweren depressiven Störungen; NBI-1117568 zur Behandlung von Schizophrenie; NBI-1070770 zur Behandlung von schweren depressiven Störungen; und NBI-1117570, NBI-1117567, NBI-1117569 und NBI-1065890 für neuropsychiatrische und neurologische Erkrankungen.
Mehr anzeigen Neurocrine Biosciences, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Neurocrine Biosciences im Vergleich zum Marktanteil des Unternehmens? N1BI34 grundlegende Statistiken Marktanteil R$67.89b Gewinn(TTM ) R$1.73b Umsatz(TTM ) R$13.68b
39.2x Kurs-Gewinn-Verhältnis
5.0x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) N1BI34 Gewinn- und Verlustrechnung (TTM ) Einnahmen US$2.41b Kosten der Einnahmen US$870.60m Bruttogewinn US$1.54b Sonstige Ausgaben US$1.24b Umsatz US$305.80m
Zuletzt gemeldete Gewinne
Mar 31, 2025
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 3.09 Bruttomarge 63.91% Nettogewinnspanne 12.68% Schulden/Eigenkapital-Verhältnis 0%
Wie hat sich N1BI34 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/05/17 20:31 Aktienkurs zum Tagesende 2025/05/15 00:00 Gewinne 2025/03/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Neurocrine Biosciences, Inc. wird von 45 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Martha Freitag Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
42 weitere Analysten anzeigen 
